Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
KYTX
Upturn stock ratingUpturn stock rating

Kyverna Therapeutics, Inc. Common Stock (KYTX)

Upturn stock ratingUpturn stock rating
$3.07
Last Close (24-hour delay)
Profit since last BUY18.99%
upturn advisory
Consider higher Upturn Star rating
BUY since 24 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: KYTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $17.2

1 Year Target Price $17.2

Analysts Price Target For last 52 week
$17.2Target price
Low$1.78
Current$3.07
high$11.4

Analysis of Past Performance

Type Stock
Historic Profit 18.99%
Avg. Invested days 24
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 141.76M USD
Price to earnings Ratio -
1Y Target Price 17.2
Price to earnings Ratio -
1Y Target Price 17.2
Volume (30-day avg) 6
Beta -
52 Weeks Range 1.78 - 11.40
Updated Date 06/30/2025
52 Weeks Range 1.78 - 11.40
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.24

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -31.08%
Return on Equity (TTM) -49.72%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -93953097
Price to Sales(TTM) -
Enterprise Value -93953097
Price to Sales(TTM) -
Enterprise Value to Revenue 3341.48
Enterprise Value to EBITDA -
Shares Outstanding 43218900
Shares Floating 22191595
Shares Outstanding 43218900
Shares Floating 22191595
Percent Insiders 12.04
Percent Institutions 68.49

Analyst Ratings

Rating 3
Target Price 17.2
Buy 3
Strong Buy 3
Buy 3
Strong Buy 3
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Kyverna Therapeutics, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. Founded in 2020, it aims to revolutionize treatment for patients with severe autoimmune conditions.

business area logo Core Business Areas

  • Cell Therapy Development: Developing engineered T cell therapies to selectively target and eliminate autoreactive B cells, addressing the root cause of autoimmune diseases.

leadership logo Leadership and Structure

Peter Maag, PhD, is the CEO. The company operates with a structure typical of a biotech firm, focusing on research, clinical development, and strategic partnerships.

Top Products and Market Share

overview logo Key Offerings

  • KYV-101: KYV-101 is Kyverna's lead asset, a fully human CD19 CAR T-cell therapy being investigated for multiple autoimmune diseases, including lupus nephritis, systemic sclerosis, and myasthenia gravis. Phase 1/2 studies are ongoing. Competitors include companies developing similar CAR-T therapies or alternative treatments for autoimmune diseases, such as GSK (Benlysta for lupus).

Market Dynamics

industry overview logo Industry Overview

The autoimmune disease therapeutics market is large and growing, with a significant unmet need for more effective and durable treatments. CAR-T therapy represents a novel approach with potential for long-term remission.

Positioning

Kyverna is positioning itself as a leader in the development of CAR-T therapies for autoimmune diseases, differentiating itself through its fully human CAR-T construct and focus on specific patient populations.

Total Addressable Market (TAM)

The TAM for autoimmune disease therapies is estimated to be over $100 billion globally. Kyverna, with its CAR-T approach, is targeting a portion of this market by offering potentially curative treatments. Their positioning focuses on specific niches with high unmet need.

Upturn SWOT Analysis

Strengths

  • Novel CAR-T approach for autoimmune diseases
  • Fully human CAR-T construct potentially reducing immunogenicity
  • Strong management team with experience in cell therapy
  • Focus on specific autoimmune indications with high unmet need

Weaknesses

  • Early stage of development (clinical trials)
  • High manufacturing costs associated with cell therapies
  • Potential safety concerns with CAR-T therapies (e.g., cytokine release syndrome)
  • Dependence on single lead asset (KYV-101)

Opportunities

  • Expanding KYV-101 to additional autoimmune indications
  • Securing partnerships with larger pharmaceutical companies
  • Advancements in CAR-T manufacturing to reduce costs
  • Positive clinical trial data demonstrating efficacy and safety

Threats

  • Competition from other companies developing CAR-T therapies or alternative treatments
  • Regulatory hurdles and approval delays
  • Negative clinical trial results
  • Changes in reimbursement policies for cell therapies

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • GILD
  • JNJ

Competitive Landscape

Kyverna faces competition from established pharmaceutical companies developing traditional autoimmune therapies, as well as other biotech companies developing cell and gene therapies. Kyverna differentiates itself by focusing on a fully human CAR-T construct and specific patient populations.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by preclinical development and entry into clinical trials.

Future Projections: Future growth is dependent on successful clinical trial outcomes and potential commercialization of KYV-101.

Recent Initiatives: Recent initiatives include enrolling patients in ongoing clinical trials, presenting clinical data at scientific conferences, and securing additional funding.

Summary

Kyverna Therapeutics is a promising clinical-stage biotech company pioneering CAR-T therapies for autoimmune diseases. Its lead asset, KYV-101, shows potential, but the company faces risks associated with clinical development, manufacturing costs, and competition. Successful clinical trials and strategic partnerships are crucial for its future growth. Investors should closely monitor trial results and regulatory developments.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • Clinical trial data

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a financial professional.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Kyverna Therapeutics, Inc. Common Stock

Exchange NASDAQ
Headquaters Emeryville, CA, United States
IPO Launch date 2024-02-08
CEO & Director Mr. Warner Biddle
Sector Healthcare
Industry Biotechnology
Full time employees 119
Full time employees 119

Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.